Michael Kowolenko - Net Worth and Insider Trading

Michael Kowolenko Net Worth

The estimated net worth of Michael Kowolenko is at least $4 Million dollars as of 2024-04-23. Michael Kowolenko is the SVP, Pharm Ops & Technology of Biogen Inc and owns about 18,124 shares of Biogen Inc (BIIB) stock worth over $4 Million. Details can be seen in Michael Kowolenko's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Michael Kowolenko has not made any transactions after 2007-07-25 and currently still holds the listed stock(s).

Transaction Summary of Michael Kowolenko

To

Michael Kowolenko Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Michael Kowolenko owns 1 companies in total, including Biogen Inc (BIIB) .

Click here to see the complete history of Michael Kowolenko’s form 4 insider trades.

Insider Ownership Summary of Michael Kowolenko

Ticker Comapny Transaction Date Type of Owner
BIIB Biogen Inc 2007-07-25 SVP & Pharm Ops & Technology

Michael Kowolenko Latest Holdings Summary

Michael Kowolenko currently owns a total of 1 stock. Michael Kowolenko owns 18,124 shares of Biogen Inc (BIIB) as of July 25, 2007, with a value of $4 Million.

Latest Holdings of Michael Kowolenko

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BIIB Biogen Inc 2007-07-25 18,124 194.23 3,520,225

Holding Weightings of Michael Kowolenko


Michael Kowolenko Form 4 Trading Tracker

According to the SEC Form 4 filings, Michael Kowolenko has made a total of 0 transactions in Biogen Inc (BIIB) over the past 5 years. The most-recent trade in Biogen Inc is the sale of 20,507 shares on July 25, 2007, which brought Michael Kowolenko around $1 Million.

Insider Trading History of Michael Kowolenko

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Michael Kowolenko Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Michael Kowolenko Ownership Network

Ownership Network List of Michael Kowolenko

No Data

Ownership Network Relation of Michael Kowolenko


Michael Kowolenko Owned Company Details

What does Biogen Inc do?

Who are the key executives at Biogen Inc?

Michael Kowolenko is the SVP & Pharm Ops & Technology of Biogen Inc. Other key executives at Biogen Inc include Head of Development Priya Singhal , Head of Research Jane Grogan , and EVP & Human Resources Ginger Gregory .

Biogen Inc (BIIB) Insider Trades Summary

Over the past 18 months, Michael Kowolenko made no insider transaction in Biogen Inc (BIIB). Other recent insider transactions involving Biogen Inc (BIIB) include a net sale of 2,797 shares made by Priya Singhal , a net sale of 8,291 shares made by Ginger Gregory , and a net sale of 5,532 shares made by Susan H Alexander .

In summary, during the past 3 months, insiders sold 1,516 shares of Biogen Inc (BIIB) in total and bought 455 shares, with a net sale of 1,061 shares. During the past 18 months, 16,620 shares of Biogen Inc (BIIB) were sold and 455 shares were bought by its insiders, resulting in a net sale of 16,165 shares.

Biogen Inc (BIIB)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Biogen Inc Insider Transactions

No Available Data

Michael Kowolenko Mailing Address

Above is the net worth, insider trading, and ownership report for Michael Kowolenko. You might contact Michael Kowolenko via mailing address: 14 Cambridge Center, Cambridge Ma 02142.

Discussions on Michael Kowolenko

No discussions yet.